JUNS · Jupiter Neurosciences Inc. Common Stock
View on chartInsiders & Stakes
| ROSEN CHRISTER CEO and Chairman | ▲ Buy | Open Market | 11,078,892 Shares held | 7/1/2025 | View profile |
| Hayward Marshall A. Chief Scientific Officer | ▲ Buy | Option Exercise | 2,995,077 Shares held | 3/2/2026 | View profile |
| Rosen Alexander Gustaf Erik Chief Administrative Officer | ▲ Buy | Option Exercise | 617,411 Shares held | 6/2/2025 | View profile |
| Silva Alison D. Pres + Chief Business Officer | ▲ Buy | Open Market | 112,777 Shares held | 7/1/2025 | View profile |
| Holger Weis Director | ▲ Buy | Option Exercise | 96,581 Shares held | 6/2/2025 | View profile |
| Hemmerly Nicholas H. Director | ▲ Buy | Option Exercise | 95,550 Shares held | 6/2/2025 | View profile |
| Kampf Julie B. Director | ▲ Buy | Option Exercise | 82,875 Shares held | 6/2/2025 | View profile |
| Elmasri Saleem CFO and Secretary | ▲ Buy | Option Exercise | 66,239 Shares held | 6/2/2025 | View profile |
| Brady Allison W Director | ▲ Buy | Option Exercise | 21,750 Shares held | 1/22/2025 | View profile |
Transaction History
| Hayward Marshall A. | ▲ Buy | Option Exercise | 225,000 | — | 3/2/2026 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $259 | 7/1/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 500 | $505 | 7/1/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 3,100 | $3K | 7/1/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $257 | 7/1/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $257 | 7/1/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 100 | $102 | 6/30/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $255 | 6/30/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $258 | 6/30/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $259 | 6/30/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 100 | $105 | 6/30/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 1,000 | $980 | 6/30/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 2,000 | $2K | 6/30/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 1,450 | $1K | 6/30/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 700 | $721 | 6/30/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 1,500 | $2K | 6/30/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 1,000 | $1K | 6/30/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $261 | 6/27/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 100 | $103 | 6/27/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $250 | 6/27/2025 |
| Silva Alison D. | ▲ Buy | Open Market | 250 | $263 | 6/27/2025 |
| ROSEN CHRISTER | ▲ Buy | Open Market | 166 | $176 | 6/27/2025 |
| Silva Alison D. | ▲ Buy | Option Exercise | 110,227 | $0 | 6/2/2025 |
| Rosen Alexander Gustaf Erik | ▲ Buy | Option Exercise | 96,608 | — | 6/2/2025 |
| Hayward Marshall A. | ▲ Buy | Option Exercise | 389,793 | — | 6/2/2025 |
| Hayward Marshall A. | ▲ Buy | Option Exercise | 399,402 | — | 6/2/2025 |
| Hemmerly Nicholas H. | ▲ Buy | Option Exercise | 95,550 | — | 6/2/2025 |
| Holger Weis | ▲ Buy | Option Exercise | 85,800 | — | 6/2/2025 |
| Elmasri Saleem | ▲ Buy | Option Exercise | 66,293 | $0 | 6/2/2025 |
| Kampf Julie B. | ▲ Buy | Option Exercise | 82,875 | — | 6/2/2025 |
| Rosen Alexander Gustaf Erik | ▲ Buy | Option Exercise | 164,553 | — | 6/2/2025 |
| ROSEN CHRISTER | ▲ Buy | Option Exercise | 497,396 | $0 | 6/2/2025 |
| ROSEN CHRISTER | ▲ Buy | Option Exercise | 476,070 | $0 | 6/2/2025 |
| Holger Weis | ▲ Buy | Option Exercise | 10,781 | — | 1/22/2025 |
| Brady Allison W | ▲ Buy | Option Exercise | 21,750 | — | 1/22/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
JUNS doses first patient in Phase 2a Parkinson’s trial
Jupiter Neurosciences reported that the first participant has been dosed in its Phase 2a RESET trial of JOTROL for Parkinson’s disease. The company also said it is reviewing strategic options to enhance shareholder value. The trial start follows recent mixed movement in healthcare stocks, but the dosing event provides a specific catalyst for the company.
JUNS doses first patient in Phase 2a Parkinson’s trial. Jupiter Neurosciences reported that the first participant has been dosed in its Phase 2a RESET trial of JOTROL for Parkinson’s disease. The company also said it is reviewing strategic options to enhance shareholder value. The trial start follows recent mixed movement in healthcare stocks, but the dosing event provides a specific catalyst for the company.